Literature DB >> 26362282

Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.

Rafid Kasir1, Salam Zakko2, Philip Zakko3, Michael Adler3, Aaron Lee3, Sachin Dhingra3, Cecile Guttermuth3.   

Abstract

BACKGROUND: Antibiotics for presumed small intestinal bacterial overgrowth have been shown to improve irritable bowel syndrome symptoms in at least 40% of subjects. A lactulose breath test for small intestinal bacterial overgrowth has been used to select patients who will respond. However, its predictive value, using the classic definition of a positive lactulose breath test, has been disappointing. AIMS: We conducted a retrospective evaluation to study characteristics of the lactulose breath test that may be predictive of a response to antibiotics in patients with the irritable bowel syndrome.
METHODS: A clinical practice database was interrogated for consecutive patients who had a lactulose breath test for irritable bowel syndrome symptoms and a subsequent antibiotic course. Hydrogen + methane levels with carbon dioxide correction were plotted against time. Various profiles of the breath test curves were catalogued and compared with respect to their predictive value for symptom response to antibiotics.
RESULTS: Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time. Of subjects whose hydrogen + methane rise was <20 ppm throughout the test (group 1; N = 95), 94.7% improved after antibiotics (95% CI 90.1-99.3). Of those with a rise <20 ppm within the first 90 min but a rise >50 ppm thereafter (group 3; N = 53), 47.2% improved (95% CI 33.7-60.6). The difference between groups 1 and 3 was statistically significant P < 0.001.
CONCLUSION: A lactulose breath test appears to be useful in predicting response to antibiotics in patients with the irritable bowel syndrome. A hydrogen + methane rise <20 ppm throughout the duration of the test is most predictive. This observation contradicts the classic definition of a positive lactulose breath test.

Entities:  

Keywords:  Antibiotics; Flat line; IBS; Irritable bowel syndrome; Lactulose breath test; SIBO; Small intestinal bacterial overgrowth

Mesh:

Substances:

Year:  2015        PMID: 26362282     DOI: 10.1007/s10620-015-3872-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

Authors:  E C Lauritano; M Gabrielli; A Lupascu; A Santoliquido; G Nucera; E Scarpellini; F Vincenti; G Cammarota; R Flore; P Pola; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2005-07-01       Impact factor: 8.171

Review 2.  Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy.

Authors:  Richard J Saad; William D Chey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-01       Impact factor: 11.382

Review 3.  Small intestinal bacterial overgrowth: what it is and what it is not.

Authors:  Eamonn M M Quigley
Journal:  Curr Opin Gastroenterol       Date:  2014-03       Impact factor: 3.287

4.  Small intestinal bacterial overgrowth in patients with irritable bowel syndrome.

Authors:  Iris Posserud; Per-Ove Stotzer; Einar S Björnsson; Hasse Abrahamsson; Magnus Simrén
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

5.  Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS.

Authors:  Derek Yu; Frank Cheeseman; Stephen Vanner
Journal:  Gut       Date:  2010-11-26       Impact factor: 23.059

6.  Altered intestinal microbiota in irritable bowel syndrome.

Authors:  K J Lee; J Tack
Journal:  Neurogastroenterol Motil       Date:  2010-05       Impact factor: 3.598

7.  Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics.

Authors:  I Esposito; A de Leone; G Di Gregorio; S Giaquinto; L de Magistris; A Ferrieri; G Riegler
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

8.  Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial.

Authors:  M Majewski; R W McCallum
Journal:  Adv Med Sci       Date:  2007       Impact factor: 3.287

9.  The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects.

Authors:  Anna Kassinen; Lotta Krogius-Kurikka; Harri Mäkivuokko; Teemu Rinttilä; Lars Paulin; Jukka Corander; Erja Malinen; Juha Apajalahti; Airi Palva
Journal:  Gastroenterology       Date:  2007-04-14       Impact factor: 22.682

Review 10.  The epidemiology of irritable bowel syndrome.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Clin Epidemiol       Date:  2014-02-04       Impact factor: 4.790

View more
  5 in total

1.  The Lactulose Breath Test in Irritable Bowel Syndrome: Is It All Hot Air?

Authors:  Rebecca E Burgell; Peter R Gibson
Journal:  Dig Dis Sci       Date:  2016-03       Impact factor: 3.199

2.  Poor reproducibility of breath hydrogen testing: Implications for its application in functional bowel disorders.

Authors:  Chu K Yao; Caroline J Tuck; Jacqueline S Barrett; Kim Ek Canale; Hamish L Philpott; Peter R Gibson
Journal:  United European Gastroenterol J       Date:  2016-07-07       Impact factor: 4.623

Review 3.  Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.

Authors:  Hyo Jeong Lee; Jong Kyoung Choi; Han Seung Ryu; Chang Hwan Choi; Eun Hee Kang; Kyung Sik Park; Yang Won Min; Kyoung Sup Hong
Journal:  J Neurogastroenterol Motil       Date:  2017-01-30       Impact factor: 4.924

Review 4.  Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.

Authors:  L Gatta; C Scarpignato
Journal:  Aliment Pharmacol Ther       Date:  2017-01-12       Impact factor: 8.171

5.  Association of Differential Metabolites With Small Intestinal Microflora and Maternal Outcomes in Subclinical Hypothyroidism During Pregnancy.

Authors:  Jingjing Li; Yajuan Xu; Yanjun Cai; Miao Zhang; Zongzong Sun; Yanjie Ban; Shanshan Zhai; Yingqi Hao; Qian Ouyang; Bo Wu; Mengqi Wang; Wentao Wang
Journal:  Front Cell Infect Microbiol       Date:  2022-01-07       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.